MX2021007444A - Proteina biespecifica. - Google Patents

Proteina biespecifica.

Info

Publication number
MX2021007444A
MX2021007444A MX2021007444A MX2021007444A MX2021007444A MX 2021007444 A MX2021007444 A MX 2021007444A MX 2021007444 A MX2021007444 A MX 2021007444A MX 2021007444 A MX2021007444 A MX 2021007444A MX 2021007444 A MX2021007444 A MX 2021007444A
Authority
MX
Mexico
Prior art keywords
bispecific protein
glp
peptide
gcgr antibody
mutant
Prior art date
Application number
MX2021007444A
Other languages
English (en)
Spanish (es)
Inventor
Weikang Tao
Lianshan Zhang
Qiyue Hu
Xiao Luo
Zhuoxiao Cao
Ning He
Original Assignee
Jiangsu Hengrui Medicine Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Jiangsu Hengrui Medicine Co filed Critical Jiangsu Hengrui Medicine Co
Publication of MX2021007444A publication Critical patent/MX2021007444A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/26—Glucagons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/605—Glucagons
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2869—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against hormone receptors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/524—CH2 domain
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/626—Diabody or triabody
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/71—Decreased effector function due to an Fc-modification
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/70—Fusion polypeptide containing domain for protein-protein interaction
    • C07K2319/74—Fusion polypeptide containing domain for protein-protein interaction containing a fusion for binding to a cell surface receptor
    • C07K2319/75—Fusion polypeptide containing domain for protein-protein interaction containing a fusion for binding to a cell surface receptor containing a fusion for activation of a cell surface receptor, e.g. thrombopoeitin, NPY and other peptide hormones

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Endocrinology (AREA)
  • Diabetes (AREA)
  • Engineering & Computer Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Hematology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Toxicology (AREA)
  • Emergency Medicine (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Obesity (AREA)
  • Epidemiology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
MX2021007444A 2018-12-21 2019-12-20 Proteina biespecifica. MX2021007444A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
CN201811573634 2018-12-21
CN201811606887 2018-12-27
PCT/CN2019/126903 WO2020125744A1 (zh) 2018-12-21 2019-12-20 双特异性蛋白

Publications (1)

Publication Number Publication Date
MX2021007444A true MX2021007444A (es) 2021-08-05

Family

ID=71102514

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2021007444A MX2021007444A (es) 2018-12-21 2019-12-20 Proteina biespecifica.

Country Status (11)

Country Link
US (1) US20220153853A1 (enExample)
EP (1) EP3901173A4 (enExample)
JP (1) JP2022516439A (enExample)
KR (1) KR20210109552A (enExample)
CN (2) CN112996811B (enExample)
AU (1) AU2019410643A1 (enExample)
BR (1) BR112021011595A2 (enExample)
CA (1) CA3123979A1 (enExample)
MX (1) MX2021007444A (enExample)
TW (1) TW202024134A (enExample)
WO (1) WO2020125744A1 (enExample)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2022083720A1 (zh) * 2020-10-23 2022-04-28 江苏恒瑞医药股份有限公司 Glp1-gcgr抗体融合蛋白变体及包含其的组合物
CN114685644A (zh) * 2020-12-29 2022-07-01 苏州康宁杰瑞生物科技有限公司 一种人glp-1多肽变体及其应用
IL330385A (en) 2023-12-29 2026-08-01 Jiangsu Hengrui Pharmaceuticals Co Ltd Antibody-polypeptide conjugate and its pharmaceutical use

Family Cites Families (49)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5641870A (en) 1995-04-20 1997-06-24 Genentech, Inc. Low pH hydrophobic interaction chromatography for antibody purification
AU723694B2 (en) 1996-06-05 2000-08-31 Roche Diagnostics Gmbh Exendin analogues, processes for their preparation and medicaments containing them
DE69916811T2 (de) 1998-02-27 2005-04-14 Novo Nordisk A/S Glp-1 derivate mit einem helix-gehalt über 25 %, die partiell strukturierte mizellenartige aggregate bilden
AU3247799A (en) 1998-02-27 1999-09-15 Novo Nordisk A/S Glp-1 derivatives of glp-1 and exendin with protracted profile of action
JP2002508162A (ja) 1998-02-27 2002-03-19 ノボ ノルディスク アクティーゼルスカブ Ｎ末端を短縮したｇｌｐ−１誘導体
SI1724284T1 (sl) 2000-12-07 2009-12-31 Lilly Co Eli Glp-1 fuzijski proteini
CN101665538A (zh) 2003-12-18 2010-03-10 诺沃挪第克公司 与白蛋白样物质相连的新glp-1类似物
CA2580796C (en) 2004-09-24 2013-03-26 Amgen Inc. Modified fc molecules having peptides inserted in internal loop regions
EP1891105B1 (en) 2005-06-13 2012-04-11 Imperial Innovations Limited Oxyntomodulin analogues and their effects on feeding behaviour
CN100556455C (zh) 2005-09-14 2009-11-04 王庆华 一种用于预防和治疗i型糖尿病的药物复合物及其应用
CN1935846A (zh) 2005-09-14 2007-03-28 王庆华 一种用于治疗糖尿病的融合蛋白及其制备方法和应用
RS51319B (sr) 2005-09-22 2010-12-31 Biocompatibles Uk Limited GLP-l (GLUKAGON-LIKE PEPTID-l) FUZIONI POLIPEPTIDI SA POVEĆANOM OTPORNOSTI NA PEPTIDAZE
EP2007804B1 (en) 2006-04-20 2014-06-18 Amgen, Inc Glp-1 compounds
AU2007240315A1 (en) * 2006-04-20 2007-11-01 Amgen Inc. GLP-1 compound/glucagon antibody compositions
CL2007002668A1 (es) 2006-09-20 2008-05-09 Amgen Inc Proteina de union a antigeno que se une al receptor de glucagon humano; acido nucleico que la codifica; metodo de produccion; composicion farmaceutica que la comprende; y su uso para tratar o prevenir la diabetes tipo 2.
TWI428346B (zh) 2006-12-13 2014-03-01 Imp Innovations Ltd 新穎化合物及其等對進食行為影響
NZ578948A (en) 2007-02-15 2012-03-30 Univ Indiana Res & Tech Corp Glucagon/glp-1 receptor co-agonists
WO2008152403A1 (en) 2007-06-15 2008-12-18 Zealand Pharma A/S Glucagon analogues
AR070844A1 (es) 2008-03-27 2010-05-05 Lilly Co Eli Fragmento fab o anticuerpo monoclonal humanizado que comprende el fragmento fab, y su uso para la manufactura de un medicamento antagonista del polipeptido del receptor de glucagon para el tratamiento o prevencion de diabetes de tipo 1 o 2
CA2728284C (en) 2008-06-17 2019-09-10 Richard D. Dimarchi Glucagon/glp-1 receptor co-agonists
MA32970B1 (fr) 2008-12-15 2012-01-02 Zealand Pharma As Analogues du glucagon
ES2502218T3 (es) 2008-12-15 2014-10-03 Zealand Pharma A/S Análogos de glucagón
US8642540B2 (en) 2008-12-15 2014-02-04 Zealand Pharma A/S Glucagon analogues
AU2008365557A1 (en) 2008-12-15 2011-07-21 Zealand Pharma A/S Glucagon analogues
WO2010096052A1 (en) 2009-02-19 2010-08-26 Merck Sharp & Dohme Corp. Oxyntomodulin analogs
JP6054742B2 (ja) 2009-07-13 2016-12-27 ジーランド ファーマ アクティーゼルスカブ アシル化グルカゴン類似体
EP2475683A4 (en) 2009-09-08 2013-04-24 Neopharm Co Ltd GLUCAGONIC RECEPTOR ANTIBODY YOUR USE
WO2011056713A2 (en) * 2009-11-03 2011-05-12 Amylin Pharmaceuticals, Inc. Glp-1 receptor agonist compounds for obstructive sleep apnea
WO2011075393A2 (en) 2009-12-18 2011-06-23 Indiana University Research And Technology Corporation Glucagon/glp-1 receptor co-agonists
KR20130018410A (ko) 2010-03-26 2013-02-21 노보 노르디스크 에이/에스 새로운 글루카곤 유사체
AR081975A1 (es) 2010-06-23 2012-10-31 Zealand Pharma As Analogos de glucagon
US8771696B2 (en) * 2010-11-23 2014-07-08 Regeneron Pharmaceuticals, Inc. Method of reducing the severity of stress hyperglycemia with human antibodies to the glucagon receptor
JO3756B1 (ar) * 2010-11-23 2021-01-31 Regeneron Pharma اجسام مضادة بشرية لمستقبلات الجلوكاجون
US20130344524A1 (en) * 2011-03-08 2013-12-26 Sanwa Kagaku Kenkyusho Co., Ltd. Analysis method
CN102949730A (zh) 2011-09-16 2013-03-06 西藏海思科药业集团股份有限公司 特异结合glp-1受体的药物融合体
WO2013059531A1 (en) 2011-10-20 2013-04-25 Genentech, Inc. Anti-gcgr antibodies and uses thereof
HUE035803T2 (en) 2012-12-21 2018-05-28 Sanofi Sa Dual GLP1 / GIP or trigonal GLP1 / GIP / glucagon agonists
CN105189560A (zh) * 2013-05-07 2015-12-23 瑞纳神经科学公司 抗胰高血糖素受体抗体和其使用方法
CN104231083A (zh) * 2013-06-09 2014-12-24 杭州鸿运华宁生物医药工程有限公司 抗胰高血糖素受体的抗体及其用途
RU2016117052A (ru) 2013-10-01 2017-11-10 Глэксосмитклайн Интеллекчуал Проперти Дивелопмент Лимитед Соединения для аффинной хроматографии и для продления времени полужизни терапевтического средства
US9988429B2 (en) * 2013-10-17 2018-06-05 Zealand Pharma A/S Glucagon analogues
AU2014345570B2 (en) 2013-11-06 2019-01-24 Zealand Pharma A/S Glucagon-GLP-1-GIP triple agonist compounds
EP3151855B1 (en) * 2014-06-08 2021-11-24 REMD Biotherapeutics, Inc. Methods for treating type 1 diabetes using glucagon receptor antagonistic antibodies
CN104327187B (zh) 2014-10-11 2018-06-08 上海兴迪金生物技术有限公司 一种重组人GLP-1-Fc融合蛋白
CN104293834B (zh) 2014-10-11 2018-03-23 上海兴迪金生物技术有限公司 GLP‑1或其类似物与抗体Fc片段融合蛋白的制备方法
CN107614695B (zh) 2015-04-02 2022-01-25 瑞美德生物医药科技有限公司 用胰高血糖素受体拮抗性抗体治疗肥胖症和非酒精性脂肪肝病或非酒精性脂肪性肝炎的方法
EP3394091A4 (en) 2015-12-09 2019-12-18 Merck Sharp & Dohme Corp. CO-AGONISTS OF GLUCAGON AND GLP-1 RECEPTORS
JP7005638B2 (ja) 2017-01-27 2022-02-04 エヌジーエム バイオファーマシューティカルス，インコーポレーテッド グルカゴン受容体結合タンパク質及びその使用方法
CN110357959B (zh) * 2018-04-10 2023-02-28 鸿运华宁（杭州）生物医药有限公司 Gcgr抗体及其与glp-1的融合蛋白质，以及其药物组合物和应用

Also Published As

Publication number Publication date
EP3901173A1 (en) 2021-10-27
CN115947849A (zh) 2023-04-11
CN115947849B (zh) 2026-05-12
CA3123979A1 (en) 2020-06-25
WO2020125744A1 (zh) 2020-06-25
US20220153853A1 (en) 2022-05-19
TW202024134A (zh) 2020-07-01
EP3901173A4 (en) 2022-11-23
JP2022516439A (ja) 2022-02-28
KR20210109552A (ko) 2021-09-06
AU2019410643A1 (en) 2021-08-12
CN112996811B (zh) 2022-11-22
BR112021011595A2 (pt) 2021-11-30
CN112996811A (zh) 2021-06-18

Similar Documents

Publication Publication Date Title
CL2019001465A1 (es) Nuevos compuestos como agonistas peptídicos trigonales de los receptores de glp1/glucagón/gip.
MX2019011660A (es) Anticuerpos biespecificos que se unen al receptor 2 del factor de crecimiento humano (erbb-2) y receptor 3 del factor de crecimiento humano (erbb3) para usarse en el tratamiento de celulas que tienen un gen de fusion de neuregulina-1 (nrg1).
CO2020016619A2 (es) Anticuerpos biespecificos anti-pvrig/anti-tigit y métodos de uso
CO2021008568A2 (es) Anticuerpos que se unen a cd3
CO2017000510A2 (es) Constructos de car
CO2021009693A2 (es) Proteínas de unión a antígeno del receptor gamma anti-il2
CO2017000507A2 (es) Receptor quimérico de antígeno bcma
DOP2018000212A (es) Moléculas de unión a bcma y métodos de uso de las mismas
CO2017001573A2 (es) Receptor quimérico de antígeno anti-cd123
UY36370A (es) Polipéptidos fgf-21 modificados y sus usos
ECSP18096095A (es) Anticuerpos a la alfa-sinucleína y usos de los mismos
MX2018004531A (es) Proteinas de union a antigeno que activan el receptor de leptina.
SV2017005548A (es) Proteinas de fusion
NI202000051A (es) Anticuerpos monoclonales y métodos para utilizar los mismos.
MX2018010733A (es) Celulas que expresan multiples moleculas del receptor de antigeno quimerico (car) y usos de las mismas.
MX2018009011A (es) Anticuerpos anti receptor 1 transmembrana de tirosina-proteina cinasa (ror1) y usos de los mismos.
UY32812A (es) Anticuerpos humanos de alta afinidad para angiopoyetina -2 humana.
ECSP21052193A (es) Tratamiento de cefalea por uso excesivo de medicamentos usando anticuerpos anti-cgrp o anti-cgrp-r
AR106144A1 (es) Un conjugado de proteína que comprende polipéptidos fisiológicos y una región fc inmunoglobulina
PE20161210A1 (es) Anticuerpos anti-mcam y metodos de uso asociados
MX387454B (es) DsbA Y DsbC ULTRAPURIFICADO Y MÉTODOS PARA ELABORARLOS Y UTILIZARLOS.
MX2021002225A (es) Composiciones y metodos para la reprogramacion de tcr mediante el uso de proteinas de fusion.
CO2019009035A2 (es) Proteínas de unión al receptor de glucagón y métodos para usarlas
BR112021011595A2 (pt) Proteína biespecífica
ECSP20014569A (es) Métodos para el tratamiento de enfermedades relacionadas con tnf - alfa